Membrane Signaling by Complement C5b-9, the Membrane Attack Complex

Overview

Journal Immunol Res

Specialty Allergy & Immunology

Date 1993 Jan 1

PMID 8288945

Citations 46

Authors

A Nicholson-Weller

J A Halperin

Affiliations

Soon will be listed here.

Abstract

The terminal complement complexes C5b-7, C5b-8 and C5b-9 are able to generate nonlethal cell signals. One universal consequence of a cell being targeted by C5b-8 or C5b-9 is an influx of Ca2+. In addition, other second messengers, including cAMP, inositol phosphate intermediates and arachidonate metabolites, are generated by the terminal complement complexes in specific cell types. In vivo, terminal complement complexes have been found in a wide variety of inflammatory processes in humans and in experimental animal models. Some of these models of inflammation putatively induced by terminal complement complexes have been tested in complement-deficient animals, and indeed no inflammation results, which supports the critical role of the terminal complement complexes in the pathogenesis of the lesion.

Citing Articles

Enhanced complement activation and MAC formation accelerates severe COVID-19.

Ellsworth C, Chen Z, Xiao M, Qian C, Wang C, Shamima Khatun M Cell Mol Life Sci. 2024; 81(1):405.

PMID: 39284944 PMC: 11405604. DOI: 10.1007/s00018-024-05430-w.

Unraveling the Intricate Web: Complement Activation Shapes the Pathogenesis of Sepsis-Induced Coagulopathy.

Wei X, Tu Y, Bu S, Guo G, Wang H, Wang Z J Innate Immun. 2024; 16(1):337-353.

PMID: 38815564 PMC: 11249610. DOI: 10.1159/000539502.

Emerging role of complement in COVID-19 and other respiratory virus diseases.

Xiao M, Ellsworth C, Qin X Cell Mol Life Sci. 2024; 81(1):94.

PMID: 38368584 PMC: 10874912. DOI: 10.1007/s00018-024-05157-8.

Complement Inhibition Targeted to Injury Specific Neoepitopes Attenuates Atherogenesis in Mice.

Dai S, Liu F, Ren M, Qin Z, Rout N, Yang X Front Cardiovasc Med. 2021; 8:731315.

PMID: 34651027 PMC: 8505745. DOI: 10.3389/fcvm.2021.731315.

Role of Complement Component 3 in Early Erythrolysis in the Hematoma After Experimental Intracerebral Hemorrhage.

Wang M, Xia F, Wan S, Hua Y, Keep R, Xi G Stroke. 2021; 52(8):2649-2660.

PMID: 34176310 PMC: 8316397. DOI: 10.1161/STROKEAHA.121.034372.

References

Carney D, Koski C, Shin M . Elimination of terminal complement intermediates from the plasma membrane of nucleated cells: the rate of disappearance differs for cells carrying C5b-7 or C5b-8 or a mixture of C5b-8 with a limited number of C5b-9. J Immunol. 1985; 134(3):1804-9. View

Sims P, Faioni E, Wiedmer T, Shattil S . Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem. 1988; 263(34):18205-12. View

Betz M, Seitz M, Hansch G . Thromboxane B2 synthesis in human platelets induced by the late complement components C5b-9. Int Arch Allergy Appl Immunol. 1987; 82(3-4):313-6. DOI: 10.1159/000234215. View

Weisman H, Bartow T, Leppo M, Marsh Jr H, Carson G, Concino M . Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science. 1990; 249(4965):146-51. DOI: 10.1126/science.2371562. View

Carney D, Lang T, Shin M . Multiple signal messengers generated by terminal complement complexes and their role in terminal complement complex elimination. J Immunol. 1990; 145(2):623-9. View

Holguin M, Fredrick L, Bernshaw N, Wilcox L, Parker C . Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest. 1989; 84(1):7-17. PMC: 303946. DOI: 10.1172/JCI114172. View

Ramm L, Whitlow M, Koski C, Shin M, Mayer M . Elimination of complement channels from the plasma membranes of U937, a nucleated mammalian cell line: temperature dependence of the elimination rate. J Immunol. 1983; 131(3):1411-5. View

Groggel G, Salant D, Darby C, Rennke H, Couser W . Role of terminal complement pathway in the heterologous phase of antiglomerular basement membrane nephritis. Kidney Int. 1985; 27(4):643-51. DOI: 10.1038/ki.1985.59. View

Iida K, Whitlow M, NUSSENZWEIG V . Membrane vesiculation protects erythrocytes from destruction by complement. J Immunol. 1991; 147(8):2638-42. View

10.

Mollnes T, Lea T, Mellbye O, Pahle J, Grand O, HARBOE M . Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex. Arthritis Rheum. 1986; 29(6):715-21. DOI: 10.1002/art.1780290603. View

11.

Shirazi Y, McMorris F, Shin M . Arachidonic acid mobilization and phosphoinositide turnover by the terminal complement complex, C5b-9, in rat oligodendrocyte x C6 glioma cell hybrids. J Immunol. 1989; 142(12):4385-91. View

12.

Adler S, Striker L, Striker G, Perkinson D, Hibbert J, Couser W . Studies of progressive glomerular sclerosis in the rat. Am J Pathol. 1986; 123(3):553-62. PMC: 1888270. View

13.

Mayer M . Mechanism of cytolysis by complement. Proc Natl Acad Sci U S A. 1972; 69(10):2954-8. PMC: 389682. DOI: 10.1073/pnas.69.10.2954. View

14.

Hansch G, Betz M, Gunther J, Rother K, Sterzel B . The complement membrane attack complex stimulates the prostanoid production of cultured glomerular epithelial cells. Int Arch Allergy Appl Immunol. 1988; 85(1):87-93. DOI: 10.1159/000234479. View

15.

Sandberg A, Raisz L, Wahl L, Simmons H . Enhancement of complement-mediated prostaglandin synthesis and bone resorption by arachidonic acid and inhibition by cortisol. Prostaglandins Leukot Med. 1982; 8(5):419-27. View

16.

Boom B, Baldwin W, Westedt M, Daha M, Vermeer B . Membrane attack complex of complement in leukocytoclastic vasculitis of the skin. Presence and possible pathogenetic role. Arch Dermatol. 1987; 123(9):1192-5. View

17.

Peppelenbosch M, Tertoolen L, den Hertog J, de Laat S . Epidermal growth factor activates calcium channels by phospholipase A2/5-lipoxygenase-mediated leukotriene C4 production. Cell. 1992; 69(2):295-303. DOI: 10.1016/0092-8674(92)90410-e. View

18.

Halperin J, Taratuska A, Rynkiewicz M, Nicholson-Weller A . Transient changes in erythrocyte membrane permeability are induced by sublytic amounts of the complement membrane attack complex (C5b-9). Blood. 1993; 81(1):200-5. View

19.

Suzuki S, Oldberg A, Hayman E, Pierschbacher M, Ruoslahti E . Complete amino acid sequence of human vitronectin deduced from cDNA. Similarity of cell attachment sites in vitronectin and fibronectin. EMBO J. 1985; 4(10):2519-24. PMC: 554538. DOI: 10.1002/j.1460-2075.1985.tb03965.x. View

20.

Zalman L, Wood L, MULLER-EBERHARD H . Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proc Natl Acad Sci U S A. 1986; 83(18):6975-9. PMC: 386634. DOI: 10.1073/pnas.83.18.6975. View